Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

Simvastatin Myopathy Rate Spells Trouble For High Doses In “A to Z” Trial

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

An increased rate of myopathy in study participants taking an 80 mg dose of Merck's Zocor (simvastatin) suggests that high doses of the drug "should be used with caution," according to an editorial slated for publication in the Sept. 15 Journal of the American Medical Association

You may also be interested in...



J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group

J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD

Lipitor v. Pravachol Studies Raise Questions On Utility Of OTC-Dose Statins

Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S

People In Brief

Perrigo promotes in pricing, planning
Table

View full table

Topics

Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

PS097255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By